Galectin-3 Reflects Mitral Annular Plane Systolic Excursion Being Assessed by Cardiovascular Magnetic Resonance Imaging.

. This study investigates whether serum levels of galectin-3 may reflect impaired mitral annular plane systolic excursion (MAPSE) in patients undergoing cardiac magnetic resonance imaging (cMRI). . Patients undergoing cMRI during routine clinical care were included prospectively within an all-comers design. Blood samples for biomarker measurements were collected within 24 hours following cMRI. Statistical analyses were performed in all patients and in three subgroups according to MAPSE (MAPSE I: ≥11 mm, MAPSE II: ≥8 mm-<11 mm, and MAPSE III: <8 mm). Patients with right ventricular dysfunction (<50%) were excluded. . 84 patients were included in the study. Median LVEF was 59% (IQR 51-64%). Galectin-3 correlated significantly with NT-proBNP ( = 0.42, = 0.0001). Galectin-3 increased significantly according to the different stages of impaired MAPSE ( = 0.006) and was able to discriminate both patients with impaired MAPSE <11 mm (area under the curve (AUC) = 0.645, = 0.024) and <8 mm (AUC = 0.733, = 0.003). Combining galectin-3 with NT-proBNP improved discrimination of MAPSE <8 mm (AUC 0.803, = 0.0001). In multivariable logistic regression models galectin-3 was still associated with impaired MAPSE (MAPSE < 11 mm: odds ratio (OR) = 3.53, = 0.018; MAPSE < 8 mm: OR = 3.18, = 0.06). . Galectin-3 reflects MAPSE being assessed by cardiac MRI.